REFERENCES
- Diana G.D., Pevear D.C., Otto M.J., McKinley M.A., Rossmann M.C., Smith T., Badger J. (1986) Pharmac. Ther., 42, 289–305.
- Galabov A.S. (2001) In the search of effective antivirals for treatment of (+)RNA-virus induced infections. Abstract Book Microbiologia Balkanica 2001 (2nd Balkan Conference of Microbiology, Thessaloniki, November 22–24, 2001), 37–38.
- Galabov A.S., Khristova M.L., Uzunov S., Wassilewa L., Bucher D.J., Kharitonenkov I.G. (1994) Acta virol., 38, 5–10.
- Gnann Jr. J.W. (2000) Antiviral agents. In: Infectious Diseases, (D. Armstrong, J. Cohen, eds.) vol.2 (Section 7, Anti-Infective Therapy). Mosby, London-Philadelphia, pp. 15.1–15.18.
- Gubareva L.V., Kaiser L., Hayden F.G. (2000) Influenza virus neuraminidase inhibitors. Lancet, 355, 827–835.
- Loddo B. (1980) Pharmac. Ther., 10, 431–460.
- Nikolova I., Galabov A.S. (2002) Comparative study on some genetic markers of Coxsackievirus B1 disoxaril mutants. Antiviral Res. 53/2 (Abstracts 15th Intern. Conf. on Antiviral Research, Prague, March 17–21, 2002), p.138.
- Velia S. (1999) Current therapies for AIDS. Antiviral Res. 41/2 (12th Intern. Conf. on Antiviral Research, Jerusalem, March 21–25, 1999).
- Wassilewa L., Uzunov S., Galabov A.S., Simonov A.N., Markushin S., Alexandrov M. (1995) Acta virol., 39, 79–84.